PRLDライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:16):

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients...

Stats
本日の出来高	5 376.00
平均出来高	69 111.00
時価総額	269.05M
EPS	$0 ( 2024-03-20 )
次の収益日	( $-0.470 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0.0190 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Huang Jane	Sell	9 375	Restricted Stock Unit
2024-04-04	Huang Jane	Buy	9 375	Common Stock
2024-04-04	Huang Jane	Sell	3 347	Common Stock
2024-03-01	Lim Bryant David	Buy	150 000	Employee Stock Option (right to buy)
2024-03-01	Scherle Peggy	Buy	150 000	Employee Stock Option (right to buy)

INSIDER POWER
99.32
Last 98 transactions
Buy: 26 942 964 \| Sell: 353 466

ボリューム相関

長: 0.00 (neutral)

短: 0.82 (strong)

Signal:(46.499) Same movement expected

Prelude Therapeutics 相関

10 最も正の相関
XOS	0.828

10 最も負の相関
BNIXU	-0.842

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Prelude Therapeutics 相関 - 通貨/商品

0.23
( neutral )

0.28
( neutral )

0.00
( neutral )

-0.06
( neutral )

0.38
( neutral )

Prelude Therapeutics 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.17M (0.00 %)
EPS:	$-2.02

FY	2023
収益:	$0
総利益:	$-1.17M (0.00 %)
EPS:	$-2.02

FY	2022
収益:	$0
総利益:	$-3.04M (0.00 %)
EPS:	$-2.27

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.43

Financial Reports:

No articles found.

Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.